Cevimeline hydrochloride is a cholinergic agonist primarily used in the treatment of dry mouth (xerostomia), a condition often associated with Sjögren's syndrome. It works by stimulating salivary glands to produce more saliva, which helps alleviate discomfort and improves oral health. Additionally, it is sometimes prescribed for patients experiencing dry mouth due to radiation therapy or other medical conditions. The drug mimics the action of acetylcholine, promoting secretions in the salivary and sweat glands. As a pharmaceutical reagent, it is available in high purity (≥98%) for research, development, or manufacturing applications. Patients typically take it orally, and it is important to follow dosage instructions carefully to manage potential side effects such as sweating, nausea, or gastrointestinal issues.